In-house ELISA protocols for capsid p24 detection of diverse HIV isolates.
Antibodies
Antigen
CA-p24
ELISA
HIV
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
26
06
2023
accepted:
14
11
2023
medline:
27
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
The capsid p24 (CA-p24) antigen is a component of the viral capsid of human immunodeficiency virus (HIV) that has been commonly used for clinical diagnosis and monitoring of HIV infections in Enzyme-linked Immunosorbent Assays (ELISAs). Commercial CA-p24 ELISAs are widely used in research settings, but these kits are costly and have limited breadth for detecting diverse HIV isolates. Commercial CA-p24 antibodies were used as capture and detection antibodies. Specific CA-p24 ELISAs were established with these antibodies and tested for the detection of HIV-1 isolates with the aim of developing in-house protocols to recognize HIV-1 infections in vitro for research purposes. Here we present four protocols for in-house ELISAs to detect HIV CA-p24 using commercial antibodies. The assays were able to detect the CA-p24 antigen of different HIV-1 isolates tested. Comparison between the protocols showed that these in-house ELISAs exhibit high specificity, sensitivity, and reproducibility for CA-p24 quantitation but their reactivity varied per HIV-1 isolate and subtype. These optimized ELISA protocols represent valuable tools to investigate HIV-1 infections in research facilities at a lower price than commercial CA-p24 kits.
Sections du résumé
BACKGROUND
BACKGROUND
The capsid p24 (CA-p24) antigen is a component of the viral capsid of human immunodeficiency virus (HIV) that has been commonly used for clinical diagnosis and monitoring of HIV infections in Enzyme-linked Immunosorbent Assays (ELISAs). Commercial CA-p24 ELISAs are widely used in research settings, but these kits are costly and have limited breadth for detecting diverse HIV isolates.
METHODS
METHODS
Commercial CA-p24 antibodies were used as capture and detection antibodies. Specific CA-p24 ELISAs were established with these antibodies and tested for the detection of HIV-1 isolates with the aim of developing in-house protocols to recognize HIV-1 infections in vitro for research purposes.
RESULTS
RESULTS
Here we present four protocols for in-house ELISAs to detect HIV CA-p24 using commercial antibodies. The assays were able to detect the CA-p24 antigen of different HIV-1 isolates tested. Comparison between the protocols showed that these in-house ELISAs exhibit high specificity, sensitivity, and reproducibility for CA-p24 quantitation but their reactivity varied per HIV-1 isolate and subtype.
CONCLUSIONS
CONCLUSIONS
These optimized ELISA protocols represent valuable tools to investigate HIV-1 infections in research facilities at a lower price than commercial CA-p24 kits.
Identifiants
pubmed: 37978551
doi: 10.1186/s12985-023-02242-5
pii: 10.1186/s12985-023-02242-5
pmc: PMC10656996
doi:
Substances chimiques
HIV Core Protein p24
0
Capsid Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Subventions
Organisme : Netherlands Organization of Scientific Research (NWO)
ID : ASPASIA 015.015.040
Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2021 Dec 8;11(1):23682
pubmed: 34880361
PLoS One. 2015 Apr 27;10(4):e0125701
pubmed: 25915630
Biol Direct. 2021 Dec 20;16(1):27
pubmed: 34930406
BMC Biotechnol. 2006 Jul 12;6:34
pubmed: 16836756
HIV Clin Trials. 2012 Jan-Feb;13(1):11-22
pubmed: 22306584
Sex Transm Infect. 2017 Mar;93(2):100-101
pubmed: 27272704
PLoS One. 2014 Oct 24;9(10):e111552
pubmed: 25343245
Vaccines (Basel). 2021 Feb 07;9(2):
pubmed: 33562203
Brief Funct Genomics. 2020 May 20;19(3):201-208
pubmed: 31711197
Trends Pharmacol Sci. 2022 Jan;43(1):16-29
pubmed: 34742581
STAR Protoc. 2020 Oct 14;1(3):100133
pubmed: 33377027
BMC Infect Dis. 2015 Oct 29;15:468
pubmed: 26511217
Nature. 2019 Apr;568(7751):244-248
pubmed: 30836379
PLoS Pathog. 2013;9(6):e1003461
pubmed: 23818857
J Virol. 2019 Apr 17;93(9):
pubmed: 30814280
Front Immunol. 2020 Oct 28;11:590780
pubmed: 33193428
J Virol Methods. 2014 Jul;203:88-96
pubmed: 24698763
PLoS One. 2014 Mar 06;9(3):e89826
pubmed: 24603460
J Virol. 1998 Jun;72(6):5099-107
pubmed: 9573281
Lancet HIV. 2021 Jan;8(1):e51-e58
pubmed: 33271124
PLoS One. 2021 Jul 1;16(7):e0242641
pubmed: 34197451
Cold Spring Harb Protoc. 2018 Apr 2;2018(4):
pubmed: 29610364
J Clin Virol. 2012 Oct;55(2):121-7
pubmed: 22795598
J Virol Methods. 2016 Apr;230:45-52
pubmed: 26808359
Retrovirology. 2013 Oct 31;10:126
pubmed: 24176092
Mol Ther Methods Clin Dev. 2022 Feb 26;25:43-51
pubmed: 35356755
Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29584-29594
pubmed: 33168755
J Med Virol. 2016 Jun;88(6):979-86
pubmed: 26519867
Virology. 1991 Dec;185(2):661-72
pubmed: 1683726
Retrovirology. 2006 Sep 27;3:64
pubmed: 17005036
Am J Clin Pathol. 2004 Jul;122(1):20-7
pubmed: 15272526
J Virol. 2004 Mar;78(6):2841-52
pubmed: 14990703
Nucleic Acids Res. 2020 Jun 4;48(10):5527-5539
pubmed: 32282899
Viruses. 2021 Dec 08;13(12):
pubmed: 34960730
J Clin Virol. 2011 Jan;50(1):57-60
pubmed: 20926337